The potential mechanisms of Aβ-receptor for advanced glycation end-products interaction disrupting tight junctions of the blood-brain barrier in Alzheimer's disease

References

• Lomoio S, Lopez-Gonzalez I, Aso E, Cerebellar amyloid-beta plaques: disturbed cortical circuitry in AbetaPP/PS1 transgenic mice as a model of familial Alzheimer's disease. J Alzheimer's disease: JAD 2012;31:285–300.
   PubMed Web of Science ®Google Scholar
• Biron KE, Dickstein DL, Gopaul R, Jefferies WA. Amyloid triggers extensive cerebral angiogenesis causing blood brain barrier permeability and hypervascularity in Alzheimer's disease. PloS One 2011;6:e23789.
   PubMed Web of Science ®Google Scholar
• Love S, Miners S, Palmer J, Insights into the pathogenesis and pathogenicity of cerebral amyloid angiopathy. Front Biosci 2009;14:4778–92.
   Web of Science ®Google Scholar
• Wang YJ, Zhou HD, Zhou XF. Clearance of amyloid-beta in Alzheimer's disease: progress, problems and perspectives. Drug Discov Today 2006;11:931–8.
   PubMed Web of Science ®Google Scholar
• Deane R, Bell RD, Sagare A, Zlokovic BV. Clearance of amyloid-beta peptide across the blood-brain barrier: implication for therapies in Alzheimer's disease. CNS & Neurol Disord Drug Targets 2009;8:16–30.
   PubMed Web of Science ®Google Scholar
• Sharma HS, Castellani RJ, Smith MA, Sharma A. The blood-brain barrier in Alzheimer's disease: novel therapeutic targets and nanodrug delivery. Int Rev Neurobiol 2012;102:47–90.
   PubMedGoogle Scholar
• Shen S, Zhang W. ABC transporters and drug efflux at the blood-brain barrier. Rev Neurosci 2010;21:29–53.
   PubMed Web of Science ®Google Scholar
• Ronaldson PT, Davis TP. Blood-brain barrier integrity and glial support: mechanisms that can be targeted for novel therapeutic approaches in stroke. Curr Pharm Des 2012;18:3624–44.
   PubMed Web of Science ®Google Scholar
• Correale J, Villa A. Cellular elements of the blood-brain barrier. Neurochem Res 2009;34:2067–77.
   PubMed Web of Science ®Google Scholar
• Coisne C, Engelhardt B. Tight junctions in brain barriers during central nervous system inflammation. Antioxid Redox Signal 2011;15:1285–303.
   Google Scholar
• Luissint AC, Artus C, Glacial F, Tight junctions at the blood brain barrier: physiological architecture and disease-associated dysregulation. Fluids Barriers CNS 2012;9:23.
   PubMedGoogle Scholar
• Baeten KM, Akassoglou K. Extracellular matrix and matrix receptors in blood-brain barrier formation and stroke. Dev Neurobiol 2011;71:1018–39.
   PubMed Web of Science ®Google Scholar
• Bednarczyk J, Lukasiuk K. Tight junctions in neurological diseases. Acta Neurobiol Exp (Wars) 2011;71:393–408.
   Google Scholar
• Liu WY, Wang ZB, Zhang LC, Tight junction in blood-brain barrier: an overview of structure, regulation, and regulator substances. CNS Neurosci Ther 2012;18:609–15.
   PubMed Web of Science ®Google Scholar
• Zlokovic BV. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 2008;57:178–201.
   PubMed Web of Science ®Google Scholar
• Zlokovic BV. Neurovascular mechanisms of Alzheimer's neurodegeneration. Trends Neurosci 2005;28:202–8.
   PubMed Web of Science ®Google Scholar
• Marchesi VT. Alzheimer's dementia begins as a disease of small blood vessels, damaged by oxidative-induced inflammation and dysregulated amyloid metabolism: implications for early detection and therapy. FASEB J 2011;25:5–13.
   PubMed Web of Science ®Google Scholar
• Zlokovic BV. Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. Nat Rev. Neurosci 2011;12:723–38.
   Google Scholar
• Han BH, Zhou ML, Abousaleh F, Cerebrovascular dysfunction in amyloid precursor protein transgenic mice: contribution of soluble and insoluble amyloid-beta peptide, partial restoration via gamma-secretase inhibition. J Neurosci 2008;28:13542–50.
   PubMedGoogle Scholar
• Tai LM, Holloway KA, Male DK, Amyloid-beta-induced occludin down-regulation and increased permeability in human brain endothelial cells is mediated by MAPK activation. J Cell Mol Med 2010;14:1101–12.
   PubMed Web of Science ®Google Scholar
• Carrano A, Hoozemans JJ, van der Vies SM, Amyloid Beta induces oxidative stress-mediated blood-brain barrier changes in capillary amyloid angiopathy. Antioxid Redox Signal 2011;15:1167–78.
   PubMed Web of Science ®Google Scholar
• Hartz AM, Bauer B, Soldner EL, Amyloid-beta contributes to blood-brain barrier leakage in transgenic human amyloid precursor protein mice and in humans with cerebral amyloid angiopathy. Stroke 2012;43:514–23.
   Google Scholar
• Crehan H, Hardy J, Pocock J. Microglia, Alzheimer's disease, and complement. Int J Alzheimer's Dis 2012;2012:983 640.
   Google Scholar
• Miners JS, Barua N, Kehoe PG, Abeta-degrading enzymes: potential for treatment of Alzheimer disease. J Neuropathol Exp Neurol 2011;70:944–59.
   PubMed Web of Science ®Google Scholar
• Zlokovic BV. Clearing amyloid through the blood-brain barrier. J Neurochem 2004;89:807–11.
   PubMed Web of Science ®Google Scholar
• Wilhelmus MM, Otte-Holler I, van Triel JJ, Lipoprotein receptor-related protein-1 mediates amyloid-beta-mediated cell death of cerebrovascular cells. Am J Pathol 2007;171:1989–99.
   PubMed Web of Science ®Google Scholar
• Deane R, Singh I, Sagare AP, A multimodal RAGE-specific inhibitor reduces amyloid beta-mediated brain disorder in a mouse model of Alzheimer disease. J Clin Invest 2012;122:1377–92.
   PubMed Web of Science ®Google Scholar
• RJ D. Is RAGE still a therapeutic target for Alzheimer's disease? Future Med Chem 2012;4:915–25.
   Google Scholar
• Deane R, Du Yan S, Submamaryan RK, RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat Med 2003;9:907–13.
   PubMed Web of Science ®Google Scholar
• Slowik A, Merres J, Elfgen A, Involvement of formyl peptide receptors in receptor for advanced glycation end products (RAGE) - and amyloid beta1–42-induced signal transduction in glial cells. Mol Neurodegeneration 2012;7:55.
   Google Scholar
• Yin QQ, Dong CF, Dong SQ, AGEs induce cell death via oxidative and endoplasmic reticulum stresses in both human SH-SY5Y neuroblastoma cells and rat cortical neurons. Cell Mol Neurobiol 2012;32:1299–309.
   Google Scholar
• Ohtsuki S, Ito S, Terasaki T. Is P-glycoprotein involved in amyloid-beta elimination across the blood-brain barrier in Alzheimer's disease? Clin Pharmacol Ther 2010;88: 443–5.
   Google Scholar
• Abuznait AH, Kaddoumi A. Role of ABC transporters in the pathogenesis of Alzheimer's disease. ACS Chem Neurosci 2012;3:820–31.
   PubMed Web of Science ®Google Scholar
• Fritz G. RAGE: a single receptor fits multiple ligands. Trends Biochem Sci 2011;36:625–32.
   PubMed Web of Science ®Google Scholar
• Lue LF, Walker DG, Brachova L, Involvement of microglial receptor for advanced glycation endproducts (RAGE) in Alzheimer's disease: identification of a cellular activation mechanism. Exp Neurol 2001;171:29–45.
   PubMed Web of Science ®Google Scholar
• Origlia N, Arancio O, Domenici L, Yan SS. MAPK, beta-amyloid and synaptic dysfunction: the role of RAGE. Expert Rev Neurotherapeutics 2009;9:1635–45.
   PubMed Web of Science ®Google Scholar
• Maczurek A, Shanmugam K, Munch G. Inflammation and the redox-sensitive AGE-RAGE pathway as a therapeutic target in Alzheimer's disease. Ann N Y Acad Sci 2008;1126: 147–51.
   PubMed Web of Science ®Google Scholar
• Arancio O, Zhang HP, Chen X, RAGE potentiates Abeta-induced perturbation of neuronal function in transgenic mice. EMBO J 2004;23:4096–105.
   PubMed Web of Science ®Google Scholar
• Hickman SE, Allison EK, El Khoury J. Microglial dysfunction and defective beta-amyloid clearance pathways in aging Alzheimer's disease mice. J Neurosci 2008;28:8354–60.
   PubMed Web of Science ®Google Scholar
• Hu Q, Chen C, Yan J, Therapeutic application of gene silencing MMP-9 in a middle cerebral artery occlusion-induced focal ischemia rat model. Exp Neurol 2009;216:35–46.
   PubMed Web of Science ®Google Scholar
• Cruzalegui FH, Bading H. Calcium-regulated protein kinase cascades and their transcription factor targets. Cell Mol Life Sci 2000;57:402–10.
   PubMed Web of Science ®Google Scholar
• Yang Y, Hill JW, Rosenberg GA. Multiple roles of metalloproteinases in neurological disorders. Progress in Mol Biol Translational Sci 2011;99:241–63.
   PubMed Web of Science ®Google Scholar
• Asahi M, Wang X, Mori T, Effects of matrix metalloproteinase-9 gene knock-out on the proteolysis of blood-brain barrier and white matter components after cerebral ischemia. J Neurosci 2001;21:7724–32.
   PubMed Web of Science ®Google Scholar
• Yang Y, Rosenberg GA. MMP-mediated disruption of claudin-5 in the blood-brain barrier of rat brain after cerebral ischemia. Methods Mol Biol 2011;762:333–45.
   PubMedGoogle Scholar
• Zhang YM, Zhou Y, Qiu LB, Altered expression of matrix metalloproteinases and tight junction proteins in rats following PEMF-induced BBB permeability change. Biomed Environ Sci: BES 2012;25:197–202.
   Google Scholar
• Du H, Li P, Wang J, The interaction of amyloid beta and the receptor for advanced glycation endproducts induces matrix metalloproteinase-2 expression in brain endothelial cells. Cell Mol Neurobiol 2012;32:141–7.
   Google Scholar
• Zhu P, Ren M, Yang C, Involvement of RAGE, MAPK and NF-kappaB pathways in AGEs-induced MMP-9 activation in HaCaT keratinocytes. Exp Dermatol 2012;21:123–9.
   PubMed Web of Science ®Google Scholar
• Chen D, Wei XT, Guan JH, Inhibition of c-Jun N-terminal kinase prevents blood-brain barrier disruption and normalizes the expression of tight junction proteins clautin-5 and ZO-1 in a rat model of subarachnoid hemorrhage. Acta Neurochir 2012;154:1469–76; discussion 76.
   PubMed Web of Science ®Google Scholar
• Zhang L, Jouret F, Rinehart J, AMP-activated protein kinase (AMPK) activation and glycogen synthase kinase-3beta (GSK-3beta) inhibition induce Ca2+-independent deposition of tight junction components at the plasma membrane. J Biol Chem 2011;286:16879–90.
   PubMed Web of Science ®Google Scholar
• Fujita H, Sugimoto K, Inatomi S, Tight junction proteins claudin-2 and -12 are critical for vitamin D-dependent Ca2+ absorption between enterocytes. Mol Biol Cell 2008;19:1912–21.
   PubMed Web of Science ®Google Scholar
• Kagan BL, Hirakura Y, Azimov R, The channel hypothesis of Alzheimer's disease: current status. Peptides 2002;23:1311–5.
   PubMed Web of Science ®Google Scholar
• Kook SY, Hong HS, Moon M, Abeta(1)(-)(4)(2)-RAGE interaction disrupts tight junctions of the blood-brain barrier via Ca(2)(+)-calcineurin signaling. J Neurosci 2012;32: 8845–54.
   PubMedGoogle Scholar
• Lue LF, Yan SD, Stern DM, Walker DG. Preventing activation of receptor for advanced glycation endproducts in Alzheimer's disease. Current drug targets. CNS Neurol Disord 2005;4:249–66.
   Google Scholar
• Perrone L, Sbai O, Nawroth PP, Bierhaus A. The complexity of sporadic Alzheimer's disease pathogenesis: the role of RAGE as therapeutic target to promote neuroprotection by inhibiting neurovascular dysfunction. Int J Alzheimer's Dis 2012;2012:734956.
   Google Scholar
• Pfizer, Alzheimer's Disease Cooperative Study (ADCS). A phase 2 study evaluating the efficacy and safety of PF 04494700 in mild to moderate Alzheimer's disease. Clinical Trails. gov Identifier: NCT00566397. 2007-2010. Available at: http://clinicaltrials.gov/ct2/show/NCT00566397.
   Google Scholar
• Sabbagh MN, Agro A, Bell J, PF-04494700, an oral inhibitor of receptor for advanced glycation end products (RAGE), in Alzheimer disease. Alzheimer Dis Assoc Disord 2011;25:206–12.
   PubMed Web of Science ®Google Scholar
• Yan SF, Ramasamy R, Schmidt AM. Soluble RAGE: therapy and biomarker in unraveling the RAGE axis in chronic disease and aging. Biochem Pharmacol 2010;79:1379–86.
   PubMed Web of Science ®Google Scholar
• Han SH, Kim YH, Mook-Jung I. RAGE: the beneficial and deleterious effects by diverse mechanisms of actions. Mol Cells 2011;31:91–7.
   PubMed Web of Science ®Google Scholar
• Yan FL, Zheng Y, Zhao FD. Effects of ginkgo biloba extract EGb761 on expression of RAGE and LRP-1 in cerebral microvascular endothelial cells under chronic hypoxia and hypoglycemia. Acta Neuropathol 2008;116:529–35.
   PubMed Web of Science ®Google Scholar
• AHAF (2011): The Facts on Alzheimer's Disease. 2011 01/11/11 [cited2011 03/07/11]. Available at: http://www.ahaf. org/alzheimers/about/understanding/facts.html. Last accessed 7 March 2011.
   Google Scholar